ArticleFrontiers in oncology2025
Prognostic value of lymphocyte subsets in diffuse large B cell lymphoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although some clinical prognostic parameters and gene expression features have been identified to be associated with the prognosis of diffuse large B cell lymphoma (DLBCL), clinical outcomes of DLBCL remains unpredictable. Lymphocyte subpopulations are considered to be prognostic factors for DLBCL, however due to the small sample size, conflicting views exist. Methods: 301 newly diagnosed DLBCL patients treated at our center from January 2015 to December 2019 were retrospectively analyzed to explore the relationship of lymphocyte subsets and prognosis prediction. Results: In this retrospective single-center study, patients with more severe disease, defined by either advanced Ann Arbor stage or a high-risk IPI score, consistently exhibited significantly lower percentages of CD19+ B cells, CD4+ T cells and CD4+/CD8+ ratio, while percentage of CD8+ T cells were significantly higher. There were no significant differences in percentages of CD3+ T cells and CD16+CD56+ NK cells. Correlation analysis revealed significant associations between lymphocyte subsets and clinical features such as Ann Arbor stage, IPI score, lactate dehydrogenase (LDH), beta-2 microglobulin (b2-MG), Ki-67, age, and neutrophils. Higher percentages of CD19+ B cells, CD4+ T cells, and CD16+CD56+ NK cells, a higher CD4+/CD8+ ratio, and a lower percentage of CD8+ T cells at diagnosis predicted good response after R-CHOP treatment. Multivariate analysis indicated that a low CD4+/CD8+ ratio was independently associated with worse PFS (p=0.049) and showed a trend toward worse OS (p=0.086). Patients were dichotomized into high and low groups using the median value of CD4+/CD8+ ratio, Kaplan-Meier analysis showed that patients with CD4+/CD8+ ratio ≥1.19 had significantly longer PFS and OS compared to those with CD4+/CD8+ ratio <1.19. Discussion: Lymphocyte subsets, especially CD4+/CD8+ ratio, could be recommended as a potential prognostic indicator for DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.